BioCatalystWatch
VNDAWorkspace / VNDA / OverviewCompany library

Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. (VNDA)

Price
Market cap
Next catalystDec 12, 2026Quimilza (imsidolimab) — GPP · Regulatory decisionSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Quimilza (imsidolimab)

IL-36R

PreINDP1P2P3FilingApproved
Upcoming / outlook

BYSANTI (milsaperidone)

PreINDP1P2P3FilingApproved
Upcoming / outlook

HETLIOZ (tasimelteon)

MT1 × MT2

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Quimilza (imsidolimab)

IL-36R

PreINDP1P2P3FilingApproved
Upcoming / outlook

HETLIOZ (tasimelteon)

MT1 × MT2

PreINDP1P2P3FilingApproved
Upcoming / outlook

BYSANTI (milsaperidone)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

NK-1 receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

NEREUS™ (tradipitant)

NK-1 receptor

PreINDP1P2P3FilingApproved
HETLIOZ (tasimelteon)

MT1 × MT2

PreINDP1P2P3FilingApproved
Upcoming / outlook

VSJ-110

CFTR

VTR-297

HDAC

PreINDP1P2P3FilingApproved
VTR-297

HDAC

PreINDP1P2P3FilingApproved
PONVORY

VSJ-110

CFTR

PreINDP1P2P3FilingApproved

Approved / commercial

BYSANTI (milsaperidone)

PreINDP1P2P3FilingApproved
Upcoming / outlook

BYSANTI (milsaperidone)

PreINDP1P2P3FilingApproved
Upcoming / outlook

HETLIOZ (tasimelteon)

MT1 × MT2

Approved

PreINDP1P2P3FilingApproved
PONVORY

Approved

PreINDP1P2P3FilingApproved

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

VNDA PR & News

PR & News

VNDA SEC archive